Nisa Investment Advisors
CRNX icon

Nisa Investment Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Nisa Investment Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
3,355
+153
+5% +$6.83K ﹤0.01% 1360
2025
Q4 		$149K Buy
3,202
+2
+0.1% +$89 ﹤0.01% 1304
2025
Q3 		$133K Sell
3,200
-69
-2% -$2.21K ﹤0.01% 1359
2025
Q2 		$94K Sell
3,269
-91
-3% -$2.81K ﹤0.01% 1419
2025
Q1 		$113K Buy
3,360
+6
+0.2% +$224 ﹤0.01% 1365
2024
Q4 		$171K Buy
3,354
+188
+6% +$10.5K ﹤0.01% 1334
2024
Q3 		$162K Sell
3,166
-163
-5% -$8.41K ﹤0.01% 1327
2024
Q2 		$149K Buy
3,329
+59
+2% +$2.73K ﹤0.01% 1382
2024
Q1 		$153K Buy
3,270
+58
+2% +$2.27K ﹤0.01% 1370
2023
Q4 		$114K Sell
3,212
-200
-6% -$6.13K ﹤0.01% 1406
2023
Q3 		$101K Buy
3,412
+12
+0.4% +$247 ﹤0.01% 1501
2023
Q2 		$61.3K Buy
3,400
+2,379
+233% +$47.4K ﹤0.01% 1680
2023
Q1 		$16K Buy
1,021
+970
+1,902% +$18K ﹤0.01% 2065
2022
Q4 		$1K Hold
51
– – ﹤0.01% 2413
2022
Q3 		$1K Buy
+51
New +$1.04K ﹤0.01% 2405
2022
Q2 		– Sell
-1,630
Closed -$36K – 2393
2022
Q1 		$36K Hold
1,630
– – ﹤0.01% 1923
2021
Q4 		$31K Buy
+1,630
New +$40.2K ﹤0.01% 1840

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Nisa Investment Advisors's CRNX Position: Q1 2026 in Review

Nisa Investment Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 4.8% in Q1 2026, buying an estimated $6.83K and bringing the position to 3,355 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Nisa Investment Advisors first reported a position in CRNX in Q4 2021 and has held it in 17 quarters since. The position peaked at $171K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Nisa Investment Advisors held 3,355 shares of Crinetics Pharmaceuticals worth $122K as of Q1 2026.
  • Nisa Investment Advisors bought 153 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $6.83K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1360 holding.
  • Nisa Investment Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • Nisa Investment Advisors's Crinetics Pharmaceuticals position peaked at $171K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.